1. Academician E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russia 2. Institute of Biomedical Chemistry, Moscow, Russia 3. Lomonosov Moscow State University, Moscow, Russia 4. National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia 5. State Scientific Center “Institute of Immunology”, Moscow, Russia
Vitaphospholip®, a water-soluble form of phosphatidylcholine, has been evaluated in a clinical trial aimed at reducing non-HDL-cholesterol (non-HDL-C) and triglyceride (TG) levels in patients with combined hyperlipidemia. The randomized, double-blind, placebo-controlled study included 100 patients. Vitaphospholip® or placebo was administered orally 500 mg twice a day for 12 weeks.Treatment with Vitaphospholip® resulted in a 13.2% decrease in non-HDL-C compared to 4.3% in the placebo group (p = 0.001). The absolute decrease of non-HDL-C was 0.6 mmol/l compared to -0.2 mmol/l in the placebo group (p = 0.001). The target non-HDL-C level of less than 3.4 mmol/L was achieved in 15 of 39 patients (38.5%) in the Vitaphospholip® group versus 2 of 41 patients (4.9%) in the placebo group (p = 0.000). The absolute decrease of TG in the group of patients treated with Vitaphospholip® was -0.7 mmol/l versus -0.1 mmol/L in the placebo group (p = 0.001). During therapy with Vitaphospholip®, a significant decrease in the levels of apolipoprotein B, total cholesterol, and very low-density lipoprotein cholesterol was observed. No changes in liver or kidney function, vital signs, or ECG were registered. No serious adverse events were identified. Thus, Vitaphospholip® significantly reduced the levels of non-HDL-C, TG, and atherogenic lipoprotein in patients with combined hyperlipidemia and moderate cardiovascular risk.
Kukharchuk V.V. et al. Vitaphospholip® (water-soluble phosphatidylcholine) in the treatment of combined hyperlipidemia: a randomized, placebo-controlled clinical trial // Biomeditsinskaya Khimiya. - 2025. - V. 71. -N 5. - P. 364-374.
Kukharchuk V.V. et al., "Vitaphospholip® (water-soluble phosphatidylcholine) in the treatment of combined hyperlipidemia: a randomized, placebo-controlled clinical trial." Biomeditsinskaya Khimiya 71.5 (2025): 364-374.
Kukharchuk, V. V., Ponomarenko, E. A., Lisitsa, A. V., Romashova, Yu. A., Pleshakova, T. O., Yarovaya, E. B., Kutsenko, V. A., Guseva, M. K., Ipatova, O. M., Karpova, E. A., Zubareva, M. Yu., Pyatigorsky, A. M., Ivanov, S. V., Beregovykh, V. V., Kudlai, D. A., Markin, S. S., Archakov, A. I. (2025). Vitaphospholip® (water-soluble phosphatidylcholine) in the treatment of combined hyperlipidemia: a randomized, placebo-controlled clinical trial. Biomeditsinskaya Khimiya, 71(5), 364-374.
References
Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration; Sarwar N., Sandhu M.S., Ricketts S.L., Butterworth A.S., di Angelantonio E., Boekholdt S.M., Ouwehand W., Watkins H., Samani N.J., Saleheen D., Lawlor D., Reilly M.P., Hingorani A.D., Talmud P.J., Danesh J. (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, 375(9726), 1634–1639. CrossRef Scholar google search
Do R., Willer C.J., Schmidt E.M., Sengupta S., Gao C., Peloso G.M., Gustafsson S., Kanoni S., Ganna A., Chen J., Buchkovich M.L., Mora S., Beckmann J.S., Bragg-Gresham J.L., Chang H.-Y., Demirkan A., den Hertog H.M., Donnelly L.A., Ehret G.B., Esko T., et al. (2013) Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet., 45(11), 1345–1352. CrossRef Scholar google search
Miller M., Stone N.J., Ballantyne C., Bittner V., Criqui M., Ginsberg H.N., Goldberg A.C., Howard W.J., Jacobson M.S., Kris-Etherton P.M., Lennie T.A., Levi M., Mazzone T., Pennathur S.; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease (2011) Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 123(20), 2292–2333. CrossRef Scholar google search
Marston N.A., Giugliano R.P., Im K., Silverman M.G., O'Donoghue M.L., Wiviott S.D., Ference B.A., Sabatine M.S. (2019) Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation, 140(16), 1308–1317. CrossRef Scholar google search
Ouimet M., Barrett T.J., Fisher E.A. (2019) HDL and reverse cholesterol transport. Circ. Res., 124(10), 1505–1518. CrossRef Scholar google search
Rader D.J., Alexander E.T., Weibel G.L., Billheimer J., Rothblat G.H. (2009) The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res., 50(Suppl), S189–S194. CrossRef Scholar google search
Rohatgi A., Khera A., Berry J.D., Givens E.G., Ayers C.R., Wedin K.E., Neeland I.J., Yuhanna I.S., Rader D.R., de Lemos J.A., Shaul P.W. (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med., 371(25), 2383–2393. CrossRef Scholar google search
Archakov A.I., Guseva M.K., Uchaikin V.F., Tikhonova E.G., Ipatova O.M. (2014) Medical forms of phospholipid preparations and methods for their preparation. United States Patent No. US8680061B2. Retrieved from https://patents.google.com/patent/US8680061B2/en. Scholar google search
Lokhov P.G., Maslov D.L., Balashova E.E., Trifonova O.P., Medvedeva N.V., Torkhovskaya T.I., Ipatova O.M., Archakov A.I., Malyshev P.P., Kukharchuk V.V., Shestakova E.A., Shestakova M.V., Dedov I.I. (2015) Mass spectrometry analysis of blood plasma lipidome as method of disease diagnostics, evuation of effectiveness and optimization of drug therapy. Biomeditsinskaya Khimiya, 61(1), 7–18. CrossRef Scholar google search
Kudinov V.A., Torkhovskaya T.I., Zakharova T.S., Morozevich G.E., Artyushev R.I., Zubareva M.Yu., Markin S.S. (2021) High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis. Biomed. Pharmacother., 141, 111900. CrossRef Scholar google search
Archakov A.I., Guseva M.K., Uchaikin V.F., Ipatova O.M., Tikhonova E.G., Shironin A.V. (2010) Nanoform of phospholipid preparation for oral use (sashet) and method of its obtaining (versions). Russian Patent No. RU2463057C2. Retrieved from: https://patents.google.com/patent/RU2463057C2/ru. Scholar google search
Tikhonova E.G., Sanzhakov M.A., Tereshkina Yu.A., Kostryukova L.V., Khudoklinova Yu.Yu., Orlova N.A., Bobrova D.V., Ipatova O.M. (2022) Drug transport system based on phospholipid nanoparticles: production technology and characteristics. Pharmaceutics, 14(11), 2522. CrossRef Scholar google search
Zubareva M., Kudinov V., Malyshev P., Rozhkova T., Markin S., Kukharchuk V. (2020) Usage of a new pharmacological agent of ultra-small phospholipid nanoparticles (micelles) in the treatment of combined hyperlipidemia. Eur. Heart J., 41(Suppl.2), ehaa946.3007. CrossRef Scholar google search
Robinson J.G., Wang S., Smith B.J., Jacobson T.A. (2009) Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol., 53(4), 316–322. CrossRef Scholar google search
Markin S.S., Kuharchuk V.V., Lisitsa A.V., Ponomarenko E.A., Romashova Y.A., Pleshakova T.O., Ipatova O.M., Tikhonova E.G., Guseva M.K., Kutsenko V.A., Ivanov S.V., Yarovaya E.B., Zubareva M.Y., Beregovykh V.V., Archakov A.I. (2025) Water soluble peroral pharmaceutical form of phosphatidylcholine Vitaphospholip®: experimental and clinical data in combined hyperlipidemia. Annals of the Russian Academy of Medical Sciences, 80(1), 42–48. CrossRef Scholar google search
Tardif J.-C., Karwatowska-Prokopczuk E., Amour E.S., Ballantyne C.M., Shapiro M.D., Moriarty P.M., Baum S.J., Hurh E., Bartlett V.J., Kingsbury J., Figueroa A.L., Alexander V.J., Tami J., Witztum J.L., Geary R.S., O'Dea L.S.L., Tsimikas S., Gaudet D. (2022) Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur. Heart J., 43(14), 1401–1412. CrossRef Scholar google search
Nicholls S.J., Lincoff A.M., Garcia M., Bash D., Ballantyne C.M., Barter P.J., Davidson M.H., Kastelein J.J.P., Koenig W., McGuire D.K., Mozaffarian D., Ridker P.M., Ray K.K., Katona B.G., Himmelmann A., Loss L.E., Rensfeldt M., Lundström T., Agrawal R., Menon V., Wolski K., Nissen S.E. (2020) Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA, 324(22), 2268–2280. CrossRef Scholar google search
Duan Y., Gong K., Xu S., Zhang F., Meng X., Han J. (2022) Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct. Target. Ther., 7, 265. CrossRef Scholar google search
Nicholls S.J., Puri R., Ballantyne C.M., Jukema J.W., Kastelein J.J.P., Koenig W., Wright R.S., Kallend D., Wijngaard P., Borgman M., Wolski K., Nissen S.E. (2018) Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial. JAMA Cardiology, 3(9), 806–814. CrossRef Scholar google search
Nicholls S.J., Andrews J., Kastelein J.J.P., Merkely B., Nissen S.E., Ray K.K., Schwartz G.G., Worthley S.G., Keyserling C., Dasseux J.-L., Griffith L., Kim S.W., Janssan A., di Giovanni G., Pisaniello A.D., Scherer D.J., Psaltis P.J., Butters J. (2018) Effect of serial infusions of CER-001, a pre-β high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression a cute coronary syndrome trial: a randomized clinical trial. JAMA Cardiology, 3(9), 815–822. CrossRef Scholar google search
Tardif J.-C., Grégoire J., L'Allier P.L., Ibrahim R., Lespérance J., Heinonen T.M., Kouz S., Berry C., Basser R., Lavoie M.-A., Guertin M.-C., Rodés-Cabau J.; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA, 297(15), 1675–1682. CrossRef Scholar google search
Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., Halpern S., Crowe T., Blankenship J.C., Kerensky R. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA, 290(17), 2292–2300. CrossRef Scholar google search
Day C. (1975) Obstacles to the clinical investigation of phospholipids. Artery, 1, 1–2. Scholar google search
Paavola T., Kuusisto S., Jauhiainen M., Kakko S., Kangas-Kontio T., Metso J., Soininen P., Ala-Korpela M., Bloigu R., Hannuksela M.L., Savolainen M.J., Salonurmi T. (2017) Impaired HDL2-mediated cholesterol efflux is associated with metabolic syndrome in families with early onset coronary heart disease and low HDL-cholesterol level. PLOS One, 12(2), e0171993. CrossRef Scholar google search
Luo Y., Guo Y., Wang H., Yu M., Hong K., Li D., Li R., Wen B., Hu D., Chang L., Zhang J., Yang B., Sun D., Schwendeman A.S., Chen E.Y. (2021) Phospholipid nanoparticles: therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. EBioMedicine, 74, 103725. CrossRef Scholar google search
Meikle P.J., Formosa M.F., Mellett N.A., Jayawardana K.S., Giles C., Bertovic D.A., Jennings G.L., Childs W., Reddy M., Carey A.L., Baradi A., Nanayakkara S., Wilson A.M., Duffy S.J., Kingwell B.A. (2019) HDL phospholipids, but not cholesterol distinguish acute coronary syndrome from stable coronary artery disease. J. Am. Heart Assoc., 8(11), e011792. CrossRef Scholar google search
